Baqsimi 3 mg/1 (Glucagon POWDER) 3 mg/1

Baqsimi 3 mg/1 is a nasal powder formulation of glucagon used for emergency treatment of severe hypoglycemia. This rapid-acting medication is designed for quick administration when oral glucose is not feasible.

Strength

3 mg/1

Pack Size

2 TUBE in 1 CARTON (0548-8352-02) / 1 BOTTLE, UNIT-DOSE in 1 TUBE / 1 POWDER in 1 BOTTLE, UNIT-DOSE

Manufacturer / TM Owner

Amphastar Pharmaceuticals, Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Baqsimi 3 mg/1 is primarily used for the treatment of severe hypoglycemia in diabetic patients who are unconscious or unable to swallow. It works by raising blood glucose levels quickly. This medication is often used in emergency situations where immediate intervention is required to prevent severe health complications.

Side Effects

Baqsimi 3 mg/1 is designed to rapidly increase blood glucose levels. Common effects may include nausea, vomiting, and headache. Some users may also experience temporary discomfort at the application site. The effects are typically short-lived as the body metabolizes the medication.

Precautions & Warnings

Baqsimi 3 mg/1 should be stored at room temperature and kept out of reach of children. It is important to follow the instructions provided with the medication carefully. Users should be aware of the potential for allergic reactions and seek medical attention if severe symptoms occur.

Avoid Interactions

Baqsimi 3 mg/1 may interact with other medications, including those that affect blood glucose levels. It is important to inform healthcare providers about all medications being taken. Alcohol and certain foods may also affect the efficacy of Baqsimi 3 mg/1, so users should be cautious about their intake.

Frequently Asked Questions

Baqsimi 3 mg/1 is used for the emergency treatment of severe hypoglycemia in diabetic patients who are unconscious or unable to swallow.

Baqsimi 3 mg/1 works by rapidly increasing blood glucose levels, providing quick relief in emergency situations.

Common side effects may include nausea, vomiting, headache, and temporary discomfort at the application site.

Baqsimi 3 mg/1 may interact with other medications, so it is important to inform healthcare providers about all medications being taken.

Baqsimi 3 mg/1 should be stored at room temperature and kept out of reach of children.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.